Advertisement

Standard of Care in T-Cell Lymphoma

  • Alessandro Broccoli
  • Dai Chihara
  • Michelle A. Fanale
  • Pier Luigi ZinzaniEmail author
Chapter
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

Peripheral T-cell lymphoma are rare neoplasms of the hemopoietic system with predominantly nodal presentation and aggressive behavior. Anthracycline-containing chemotherapy regimens represent the first-line treatment of choice, to be complemented with autologous transplantation in responding patients, if their clinical conditions are permissive, to consolidate remission, and to prolong survival. Nevertheless, many patients inadequately respond to chemotherapy or progress at the end of treatment. New molecules have been approved in the United States for relapsed and refractory disease, although response rates and, most of all, response durations are still rather poor when applied as single agents. Allogeneic transplantation may offer an opportunity of long-term disease control in patients with relapsed disease. This chapter reviews the current approach to peripheral T-cell lymphoma in terms of clinical evaluation, diagnosis, staging, and first-line treatment and presents possible treatment options for patients whose disease recurs after chemotherapy or appears refractory.

Keywords

Alisertib Allogeneic transplantation Autologous transplantation Belinostat Brentuximab vedotin Chemotherapy Mogamulizumab Peripheral T-cell lymphoma Pralatrexate Romidepsin 

References

  1. 1.
    Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34:963–71.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014a;164:536–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123:2915–23.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017a;129:1103–12.PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson PA, Lade S, Webster H, Ryan G, Prince HM. Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity. Haematologica. 2010;95:1977–9.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Ansell S. How to select the frontline treatment for a patient with peripheral T-cell lymphoma. Leuk Lymphoma. 2016;57:783–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Broccoli A, Zinzani PL. Angioimmunoblastic T-cell lymphoma. Hematol Oncol Clin North Am. 2017b;31:223–38.PubMedCrossRefGoogle Scholar
  11. 11.
    Corradini P, Marchetti M, Barosi G, Billio A, Gallamini A, Pileri S, et al. SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Ann Oncol. 2014;25:2339–50.PubMedCrossRefGoogle Scholar
  12. 12.
    d’Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v108–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Casulo C, Schöder H, Feeney J, Lim R, Maragulia J, Zelenetz AD, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma. 2013;54:2163–7.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Tomita N, Hattori Y, Fujisawa S, Hashimoto C, Taguchi J, Takasaki H, et al. Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. Ann Hematol. 2015;94:431–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Vose JM. International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood. 2005;106:811.Google Scholar
  18. 18.
    Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-cell lymphoma project. J Clin Oncol. 2012;31:240–6.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504.PubMedCrossRefGoogle Scholar
  21. 21.
    Au WY, Weisenburger DD, Intraqumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113:3931–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118:148–55.PubMedCrossRefGoogle Scholar
  23. 23.
    Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicentre cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25:2211–7.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–75.PubMedCrossRefGoogle Scholar
  25. 25.
    Chihara D, Fanale MA. Management of anaplastic large cell lymphoma. Hematol Oncol Clin North Am. 2017;31:209–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151:159–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–25.CrossRefPubMedGoogle Scholar
  29. 29.
    Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19(5):958–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicentre study. J Clin Oncol. 2009;27:106–13.CrossRefPubMedGoogle Scholar
  32. 32.
    Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Clemens MW, Medeiros J, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34:160–8.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32:114–20.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115:3664–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Jang MS, Baek JW, Kang DY, Kang JS, Suh KS, Kim ST. Subcutaneous panniculitis-like T-cell lymphoma: successful treatment with systemic steroid alone. J Dermatol. 2012;39:96–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111:838–45.PubMedCrossRefGoogle Scholar
  39. 39.
    Yamaguchi M, Suzuki R, Oguchi M, Asano M, Amaki J, Akiba T, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol. 2017;35:32–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol. 2011;29:4410–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Wang L, Wang Z, Chen X, Li YJ, Wang KF, Xia YF, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348–55.PubMedCrossRefGoogle Scholar
  42. 42.
    Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Chihara D, Fanale M, Noorani M, Westin JR, Nastoupil L, Hagemeister F, et al. The survival outcome of the patients with relapsed/refractory anaplastic large-cell lymphoma. Blood. 2015;126:2738.Google Scholar
  45. 45.
    Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, et al. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013;92:1041–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3776–85.PubMedCrossRefGoogle Scholar
  47. 47.
    Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(Suppl. 1):i5–i10.PubMedCrossRefGoogle Scholar
  48. 48.
    Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–22.PubMedGoogle Scholar
  49. 49.
    Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–76.PubMedCrossRefGoogle Scholar
  50. 50.
    Kim SJ, Kim K, Kim BS, Suh C, Huh J, Ko YH, et al. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol. 2009;20:390–2.PubMedCrossRefGoogle Scholar
  51. 51.
    Kogure Y, Yoshimi A, Ueda K, Nannya Y, Ichikawa M, Nakamura F, et al. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis. Ann Hematol. 2015;94:989–94.PubMedCrossRefGoogle Scholar
  52. 52.
    Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, et al. Pilot study of fixed-infusion rate gemcitabine with cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004;5:45–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Park BB, Kim WS, Suh C, Shin DY, Kim JA, Kim HG, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015;94:1845–51.PubMedCrossRefGoogle Scholar
  54. 54.
    Qi F, Dong M, He X, Li Y, Wang W, Liu P, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified. Ann Hematol. 2017;96:245–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Yao YY, Tang Y, Zhu Q, Zhuang Y, Cheng YM, Wang L, et al. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. Leuk Lymphoma. 2013;54:1194–200.PubMedCrossRefGoogle Scholar
  56. 56.
    Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9:1351–3.PubMedCrossRefGoogle Scholar
  58. 58.
    Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21:860–3.PubMedCrossRefGoogle Scholar
  59. 59.
    O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–9.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636–43.PubMedCrossRefGoogle Scholar
  61. 61.
    Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827–34.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Chihara D, Oki Y, Fayad L, Wesson E, Ruben C, Horowitz SB, et al. Phase I study of romidepsin in combination with ICE (ifosfamide, carboplatin and etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma. Blood. 2014b;124:1748.CrossRefGoogle Scholar
  65. 65.
    O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015a;33:2492–9.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Pro B, Advani RH, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year survival data from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2016;128:4144.Google Scholar
  68. 68.
    Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98:611–4.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Oki Y, Feldman T, Chihara D, Fanale MA, Connors JM, Wong S, et al. Prognostic factors in patients with relapsed or refractory systemic anaplastic large T-cell lymphoma (ALCL) receiving brentuximab vedotin and outcome after treatment failure. Hematol Oncol. 2017;35(Suppl S2):252.Google Scholar
  71. 71.
    Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137–43.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Four-year survival and durability results of brentuximab vedotin in combination with CHP in the frontline treatment of patients with CD30-expressing peripheral T-cell lymphomas. Blood. 2016;128:2993.Google Scholar
  73. 73.
    O’Connor OA, Pro B, Illidge T, Trumper LH, Larsen EK, Kennedy DA. Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL). J Clin Oncol. 2014;32(Suppl 15):TPS8612.CrossRefGoogle Scholar
  74. 74.
    Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin. Blood. 2014;123:3095–100.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLEY trial. J Clin Oncol. 2013;31:104–10.PubMedCrossRefGoogle Scholar
  76. 76.
    Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49:2869–76.PubMedCrossRefGoogle Scholar
  77. 77.
    Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121:716–23.PubMedCrossRefGoogle Scholar
  78. 78.
    Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011;52:1585–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.PubMedCrossRefGoogle Scholar
  80. 80.
    Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63.PubMedCrossRefGoogle Scholar
  81. 81.
    Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014;32:44–50.PubMedCrossRefGoogle Scholar
  82. 82.
    Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33:2399–404.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    O’Connor OA, Ozcan M, Jacobsen E, Vidal JMR, Trotman J, Demeter J. First multicenter, randomized phase 3 study in patients (pts) with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator’s choice (Lumiere trial; NCT01482962). Blood. 2015b;126:341.Google Scholar
  84. 84.
    Fanale MA, Wang Z, Ma W, Oki Y, Hagemeister FB, Fayad LE, et al. Gene expression profiling for molecular features of response in a phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B- and T-cell lymphomas. Blood. 2015;126:2705.Google Scholar
  85. 85.
    Amengual JE, Lichtenstein R, Rojas C, Sawas A, Deng C, Lichtenstien E, et al. The pralatrexate—romidepsin doublet: a well tolerated and highly effective combination for patients with relapsed or refractory peripheral T-cell lymphoma. Blood. 2016;128:1824.Google Scholar
  86. 86.
    Mehta-Shah N, Lunning MA, Boruchov AM, Ruan J, Nair S, Lynch P, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: activity in T-cell lymphoma. J Clin Oncol. 2015;33(Suppl 15):8521.Google Scholar
  87. 87.
    Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21:855–9.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14:741–7.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405–10.PubMedCrossRefGoogle Scholar
  90. 90.
    Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M, et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant. 2007;40:239–43.PubMedCrossRefGoogle Scholar
  91. 91.
    Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Jang S, et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol. 2007;86:435–42.PubMedCrossRefGoogle Scholar
  92. 92.
    Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520–6.CrossRefPubMedGoogle Scholar
  94. 94.
    Kim SW, Yoon SS, Suzuki R, Matsuno Y, Yi HG, Yoshida T, et al. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia. 2013;27:1394–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22:1608–13.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26:2264–71.PubMedCrossRefGoogle Scholar
  97. 97.
    Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol. 2010;150:170–8.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Aoki K, Suzuki R, Chihara D, Suzuki T, Kim S-W, Fukuda T, et al. Reduced-intensity conditioning of allogeneic transplantation for nodal peripheral T-cell lymphomas. Blood. 2014;124:2585.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alessandro Broccoli
    • 1
  • Dai Chihara
    • 2
  • Michelle A. Fanale
    • 3
  • Pier Luigi Zinzani
    • 1
    Email author
  1. 1.Institute of Hematology “L. e A. Seràgnoli”—University of BolognaBolognaItaly
  2. 2.Department of Internal MedicineThe University of New MexicoAlbuquerqueUSA
  3. 3.Department of Lymphoma/MyelomaThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations